According to an announcement on Tuesday from 10 Downing Street in London, Theresa May, the British Prime Minister, has committed to investing £75 million (about US$106 million) in prostate cancer research. … READ MORE …
Filed under: Uncategorized | Tagged: £75 million, Britain, research, UK | 2 Comments »
Prostate cancer patients in the UK may want to know (if they don’t already) that the erectile dysfunction drug sildenafil (Viagra) will become available as an “over the counter” or OTC drug called Viagra Connect early next year. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: counter, OTC, over, sildenafil, UK, Viagra | 1 Comment »
According to an article this morning on the PharmaTimes web site, Astellas has convinced the National Institute for Health and Care Excellence (NICE) to recommend coverage of enzalutamide (Xandi) in chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Treatment | Tagged: abiraterone, coverage, enzalutamide, NICE, UK, Xtandi, Zytiga | 3 Comments »
According to a report in the Daily Telegraph, Cancer Research UK is claiming that deaths from prostate cancer in the UK have drop by 20.8 percent during the 19-year period from 1991-93 to 2010-12. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: death, mortality, rate, UK | 1 Comment »
The National Institute for Health and Care Excellence (NICE) has issued final approval for coverage of treatment with enzalutamide (Xtandi) for men with metastatic, castrated-resistant prostate cancer (mCRPC) who have already received prior treatment with docetaxel-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: coverage, enzalutamide, NICE, UK | 7 Comments »
Apparently the British National Health Service has decided to stump up £250 million (equivalent to US$380 million) to build two proton beam radiation therapy (PBRT) units in the UK. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: proton beam, radiation, UK | 2 Comments »
According to a media release issued by Cancer Research UK a few days ago, “Boys born in 2015 will have almost three times the risk of being diagnosed with prostate cancer at some point during their lives than those born in 1990.” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: Diagnosis, incidence, reserach, risk, UK | 2 Comments »
According to information on the Prostate Cancer UK web site and in an article in The Daily Telegraph, Prostate Cancer UK is initiating a new campaign to raise money for prostate cancer research in the UK. … READ MORE …
Filed under: Uncategorized | Tagged: funding, research, UK | 2 Comments »
According to a BBC News report earlier today, abiraterone acetate has been approved for use by National Health Service (NHS) patients with metastic, castration-resistant prostate cancer (mCRPC) in Northern Ireland. A decision about availability of the drug in Scotland is expected on August 13. Abiraterone is already available to NHS patients in England and in Wales.
Filed under: Management, Treatment | Tagged: abiraterone, access, UK | 1 Comment »
According to information on the web site of the National Institute for Clinical Excellence (NICE), revised draft guidance has been issued by NICE regarding the routine use of abiraterone acetate. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, access, NICE, UK | 1 Comment »
According to recent articles in the media, the National Institute for Clinical Excellence (NICE) will shortly issue a recommendation that abiraterone is covered for routine use in the UK among men with chemotherapy-refractory, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, NICE, UK | 2 Comments »
According to a media release issued today by the National Institute for Clinical Excellence (NICE) in the UK, the institute’s advisory board will not recommend “routine” use of cabazitaxel for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, NICE, UK | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 